Logo for DiaMedica Therapeutics Inc

DiaMedica Therapeutics Investor Relations Material

Latest events

Logo for DiaMedica Therapeutics Inc

Q1 2024

DiaMedica Therapeutics
Logo for DiaMedica Therapeutics

Q1 2024

9 May, 2024
Logo for DiaMedica Therapeutics

Q4 2023

20 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from DiaMedica Therapeutics Inc

Access all reports
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious diseases, with an emphasis on acute ischemic stroke (AIS) and cardio-renal diseases. The company is dedicated to improving patient outcomes by advancing its lead product candidate, DM199, which is a synthetic version of the human tissue kallikrein-1 (KLK1) protein. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the Nasdaq.